Company Overview and News
That's a record pace for merger activity, topping the deal volume from the first few months of 2007, according to Thomson Reuters. And if this keeps up, merger activity should easily pass the all-time annual record of $4.7 trillion in deals set in 2015.
Gap Inc (NYSE:GPS) reported for its latest quarter after hours today, missing earnings expectations and posting weak Old Navy sales, sending the company’s stock on the decline.
A decline in energy shares following lower oil prices also weighed on the market, with the S&P energy index ending down 1.7 per cent.
Shares of Larsen & Toubro Infotech hit near 4-week high on Q4 profit. The stock jumped as much as 5 per cent to Rs 1,674.7, its highest since April 27.
Financial crime is wreaking widespread damage on businesses across the Asia-Pacific region and has spawned an economic underworld in which more than 40 million people work in conditions of modern slavery, according to a major new report.
U.S. stock index futures were lower on Wednesday on fresh uncertainty over U.S.-China trade talks and ahead of a Federal Reserve report that would be watched for cues on pace of future interest rate hikes.
Worries over U.S. trade protectionism, this time around car imports, weighed on Wall Street's main indexes on Thursday, overshadowing optimism that the Federal Reserve may be more tolerant of rising inflation than previously expected.
Vistra Energy Corp and Dominion Energy Inc – which serve about 5.5 million electricity customers in more than a dozen U.S. states – both say they are done building combined-cycle natural gas-fired power plants.
Netflix's stock market value ballooned to a record US$153 billion on Thursday and eclipsed Walt Disney Co for the first time, making it the world's top entertainment company and underscoring a monumental shift by viewers away from cinemas and cable television.
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Best Buy Co. Inc. (NYSE: BBY) is scheduled to release its fiscal first-quarter financial results before the markets open on Thursday. The consensus estimates from Thomson Reuters are $0.74 in EPS on $8.73 billion in revenue. In the same period of last year, the specialty retailer said it had EPS of $0.60 and $8.53 billion in revenue.
Immaterial negative news stories about Tesla Inc have hit a "fever pitch", and the electric carmaker's stock is set to surge as output of its Model 3 sedan improves, according to an analyst.
When Urban Outfitters Inc. (NASDAQ: URBN) released its first-quarter earnings report late on Tuesday, the retailer said that it had $0.38 in earnings per share (EPS) and $855.7 million in revenue. The consensus estimates from Thomson Reuters had called for $0.30 in EPS on revenue of $836.23 million. In the same period of last year, it said it had EPS of $0.10 and $761.19 million in revenue.
Tiffany & Co. (NYSE: TIF) released its fiscal first-quarter financial results before the markets opened on Wednesday. The company posted $1.14 in earnings per share (EPS) on $1.03 billion in revenue, compared with consensus estimates from Thomson Reuters that called for $0.83 in EPS on revenue of $958.17 million. In the same period of last year, the luxury retailer said it had EPS of $0.74 and $899.
Stocks were up earlier this week, but fresh warnings that a North Korea summit might not actually happen in June weighed on the indexes on Wednesday. The trend of buying the dips has not worked as well as it has in prior years, and many investors have been considering how they want their investments positioned for the longer term.
22h - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
22h - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
as of ET